Oral iloprost improves endobronchial dysplasia in former smokers.
about
Lung cancer chemoprevention: current status and future prospectsChemoprevention of lung cancer: prospects and disappointments in human clinical trialsUpdates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemopreventionEndobronchial miRNAs as biomarkers in lung cancer chemoprevention.Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.Altered histology provides a positive clinical signal in the bronchial epithelium.The BATTLE to personalize lung cancer prevention through reverse migration.Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer.Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancerWnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancerHow do we safely get people to stop smoking?Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.Randomized phase II trial of sulindac for lung cancer chemoprevention.Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers.Lung cancer screening update.Personalizing lung cancer prevention through a reverse migration strategy.Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesA Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia.Lung cancer chemoprevention: difficulties, promise and potential agents?Detection and minimally invasive treatment of early squamous lung cancer.The Second Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model.Platelet-targeted pharmacologic treatments as anti-cancer therapy.AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.Prostacyclin reverses the cigarette smoke-induced decrease in pulmonary Frizzled 9 expression through miR-31.Preinvasive Endobronchial Lesions: Lung Cancer Precursors and Risk Markers?Biomarkers of Potential Harm: Summary of an FDA-Sponsored Public Workshop.Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention
P2860
Q26995495-B34AB8D6-6CE6-4020-A116-87E43FEC4189Q28386632-A554E2E1-EC3C-4305-AADE-D15A8692DA59Q28388931-700DF40E-2C4A-4ADB-B012-BC8A3CE014AAQ34156076-D908D42A-37D5-49C0-BE0F-F7F101FA7D32Q34977797-C012624B-E75B-4E62-8A8F-D4A3C23ECD69Q35033296-2B0B6EF2-A9B3-4593-838C-C026E0FD12D9Q35208501-E65B04BB-A4F5-441F-9F93-472551F373EEQ35761033-15F5D1AF-3566-4163-B656-2D5A7B6E209CQ35870692-BDAADCB9-606B-4FD1-8C73-7F0B483B674BQ36021953-B9B4A61B-BB46-4E1F-8A99-0082836227FCQ36023746-033E97FB-7EE8-4098-B505-0752B224AEA7Q36248969-CC76743C-41BD-4C53-BAFF-B7E5081568D2Q36446587-E4C0E40A-F6F2-4CE4-94E8-CEF545DDFB44Q36592529-2D084786-A36B-45B4-AA47-AE9CBA698774Q36625590-8A7995BE-3BC0-459A-B66C-D629B8F32C9AQ36754898-2939182B-6863-4CAA-A90F-F34A463BC0A7Q37080513-02E271CA-6922-4DC9-8FA8-A1C0BEDA36CEQ37111529-7F1C02A2-B078-4B72-8EFC-0DC48C619DC7Q37470702-0C206B7D-B3ED-4BF4-B12D-802413599125Q38061199-148D2D78-083C-4323-BD8D-566BF6289AB9Q38121871-846F65C1-FC64-4731-9675-C699C03E5B9EQ38635953-3104D7AE-3D0E-4656-9085-6DFE494D42E2Q38657846-78F79F81-4F1C-44E3-B4E3-FA12583BAFA0Q38689104-D21643C0-A454-4309-B740-3952BA75BE81Q39042489-434BA3DF-7FF7-424A-9187-B93ABCE8A81CQ42544523-BC176955-AB97-44A0-92F2-4BCBD658FCB0Q43062782-93CDA84D-E3B6-4F69-866A-E548A9EB4E58Q49667007-4500D4CA-A56C-45AB-A0BA-1818CF16B491Q57135311-616A6679-EAF6-4014-B86C-699DFFFA9058
P2860
Oral iloprost improves endobronchial dysplasia in former smokers.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Oral iloprost improves endobronchial dysplasia in former smokers.
@ast
Oral iloprost improves endobronchial dysplasia in former smokers.
@en
type
label
Oral iloprost improves endobronchial dysplasia in former smokers.
@ast
Oral iloprost improves endobronchial dysplasia in former smokers.
@en
prefLabel
Oral iloprost improves endobronchial dysplasia in former smokers.
@ast
Oral iloprost improves endobronchial dysplasia in former smokers.
@en
P2093
P2860
P1476
Oral iloprost improves endobronchial dysplasia in former smokers.
@en
P2093
Daniel T Merrick
David O Wilson
Fred R Hirsch
John D Minna
John Kittelson
Mark W Geraci
Patrick J Blatchford
Paul A Bunn
Pierre P Massion
P2860
P304
P356
10.1158/1940-6207.CAPR-11-0057
P50
P577
2011-06-01T00:00:00Z